AR054186A1 - Derivados de tetrahidroindazolona y tetrahidroindolona - Google Patents
Derivados de tetrahidroindazolona y tetrahidroindolonaInfo
- Publication number
- AR054186A1 AR054186A1 ARP060100720A ARP060100720A AR054186A1 AR 054186 A1 AR054186 A1 AR 054186A1 AR P060100720 A ARP060100720 A AR P060100720A AR P060100720 A ARP060100720 A AR P060100720A AR 054186 A1 AR054186 A1 AR 054186A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- independently
- heteroaryl
- heterocycloalkyl
- Prior art date
Links
- YJJUTLWYXYQJNJ-UHFFFAOYSA-N 1,3,3a,4-tetrahydroindol-2-one Chemical compound C1C=CC=C2NC(=O)CC21 YJJUTLWYXYQJNJ-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 28
- 125000003118 aryl group Chemical group 0.000 abstract 18
- 125000001072 heteroaryl group Chemical group 0.000 abstract 14
- -1 cyano, carboxy Chemical group 0.000 abstract 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 229920006395 saturated elastomer Polymers 0.000 abstract 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 abstract 1
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical group FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003725 azepanyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65623005P | 2005-02-25 | 2005-02-25 | |
| US70571505P | 2005-08-04 | 2005-08-04 | |
| US72796505P | 2005-10-18 | 2005-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054186A1 true AR054186A1 (es) | 2007-06-06 |
Family
ID=36581601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100720A AR054186A1 (es) | 2005-02-25 | 2006-02-27 | Derivados de tetrahidroindazolona y tetrahidroindolona |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US7358370B2 (enExample) |
| EP (2) | EP2380879B1 (enExample) |
| JP (1) | JP4377942B2 (enExample) |
| KR (3) | KR101617774B1 (enExample) |
| CN (1) | CN101180275B (enExample) |
| AR (1) | AR054186A1 (enExample) |
| AU (2) | AU2006216441B2 (enExample) |
| BR (1) | BRPI0607739A2 (enExample) |
| CA (1) | CA2598993C (enExample) |
| DK (1) | DK1856057T3 (enExample) |
| EA (1) | EA013521B1 (enExample) |
| ES (1) | ES2527770T3 (enExample) |
| GE (1) | GEP20104994B (enExample) |
| IL (1) | IL185280A (enExample) |
| MA (1) | MA29713B1 (enExample) |
| MX (1) | MX2007010227A (enExample) |
| NO (1) | NO20074274L (enExample) |
| NZ (2) | NZ560685A (enExample) |
| PL (1) | PL1856057T3 (enExample) |
| PT (1) | PT1856057E (enExample) |
| SI (1) | SI1856057T1 (enExample) |
| TW (1) | TWI382015B (enExample) |
| UA (1) | UA92907C2 (enExample) |
| WO (1) | WO2006091963A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| CA2582674A1 (en) * | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for alzheimer's disease |
| KR101617774B1 (ko) * | 2005-02-25 | 2016-05-04 | 에사넥스, 인코포레이티드 | 테트라히드로인돌론 및 테트라히드로인다졸론 유도체 |
| DE602006021306D1 (enExample) * | 2005-06-27 | 2011-05-26 | Bristol Myers Squibb Co | |
| EP1991525A1 (en) * | 2006-02-27 | 2008-11-19 | Serenex, Inc. | Cyclohexylamino, benzene, pyridine, and pyridazine derivatives |
| WO2007120669A1 (en) * | 2006-04-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| CA2652263A1 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| HRP20110917T1 (hr) * | 2006-05-19 | 2012-03-31 | Abbott Laboratories | Derivati azabicikličkih alkana supstituirani fuzioniranim bicikloheterociklima aktivni u središnjem živčanom sustavu |
| WO2008005937A2 (en) * | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| CA2661436A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
| US20080076800A1 (en) * | 2006-08-24 | 2008-03-27 | Huang Kenneth H | Benzene, Pyridine, and Pyridazine Derivatives |
| US20080076813A1 (en) * | 2006-08-24 | 2008-03-27 | Huang Kenneth H | Benzene, Pyridine, and Pyridazine Derivatives |
| US20080070933A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Purine, Pyrimidine, and Azaindole Derivatives |
| US20080119457A1 (en) * | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| WO2008024961A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat-shock protein 90 inhibitors |
| US20090093452A1 (en) * | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| WO2008057246A2 (en) * | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CN101273991B (zh) * | 2007-03-28 | 2010-05-26 | 广东同德药业有限公司 | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 |
| US20080269193A1 (en) * | 2007-04-16 | 2008-10-30 | Kenneth He Huang | Tetrahydroindole and Tetrahydroindazole Derivatives |
| EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| WO2009051244A1 (ja) * | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| FR2955323B1 (fr) * | 2010-01-19 | 2015-01-16 | Sanofi Aventis | Nouveaux derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| FR2943341B1 (fr) * | 2009-03-19 | 2011-03-11 | Sanofi Aventis | Nouveaux derives d'indazole inhibiteurs d'hsp90,compositions les contenant et utilisation |
| WO2010106290A1 (fr) * | 2009-03-19 | 2010-09-23 | Sanofi-Aventis | Derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP2770327B1 (en) * | 2009-03-30 | 2017-06-14 | Nordic Bioscience A/S | Fibrosis biomarker assay |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| CN101872359B (zh) * | 2010-06-11 | 2013-08-14 | 北京邮电大学 | 实现演变点发现的社会网络演化分析方法及系统 |
| CN102311389A (zh) * | 2010-06-29 | 2012-01-11 | 王小龙 | 一种氮芳香取代吡唑衍生物、及其合成和抗癌应用 |
| CN101955461B (zh) * | 2010-10-08 | 2012-11-21 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
| CN101967125B (zh) | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| BR112013023452A2 (pt) | 2011-03-15 | 2016-12-06 | Univ British Columbia | combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata |
| CN102675288B (zh) * | 2011-03-18 | 2014-01-01 | 北京师范大学 | 2-((2-(双(2-吡啶甲基)氨基)乙基)氨基)-4-(3，6，6-三甲基-4-氧-4，5，6，7-四氢吲唑基)苯甲酰胺及制备、应用 |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法 |
| AU2012339679A1 (en) | 2011-11-14 | 2014-06-12 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with BRAF inhibitors |
| EP2879675B1 (en) | 2012-08-06 | 2019-11-13 | Duke University | Compounds and methods for targeting hsp90 |
| CN103467356B (zh) * | 2013-08-12 | 2015-04-01 | 绍兴文理学院 | 一种四氢吲哚化合物及其制备方法与应用 |
| SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| EP3191473A1 (en) * | 2014-09-11 | 2017-07-19 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
| WO2016086153A2 (en) | 2014-11-26 | 2016-06-02 | Esanex, Inc. | Use of tetrahydro!ndazolylbeimzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) |
| CN104592230B (zh) * | 2015-01-30 | 2017-02-01 | 广州暨南生物医药研究开发基地有限公司 | 一种2‑（石榴皮烷‑3‑氨基）‑4‑四氢吲唑取代的苯甲酰胺化合物及其应用 |
| CN104592203A (zh) * | 2015-01-30 | 2015-05-06 | 广州暨南生物医药研究开发基地有限公司 | 一种2-氨基-4-四氢吲唑取代的苯甲酰胺化合物及其在制备抗肿瘤药物中的应用 |
| US9737509B1 (en) | 2015-05-26 | 2017-08-22 | University Of South Florida | Antimicrobial compositions, methods of use, and methods of treatment of infections |
| WO2017059434A1 (en) | 2015-10-02 | 2017-04-06 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of cancer |
| KR102073779B1 (ko) * | 2015-10-13 | 2020-02-05 | 니혼노야쿠가부시키가이샤 | 옥심기를 가지는 축합복소환 화합물 또는 그의 염류 및 상기 화합물을 함유하는 농원예용 살충제 및 그 사용 방법 |
| WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| KR20190009346A (ko) * | 2016-05-18 | 2019-01-28 | 에사넥스, 인코포레이티드 | 암의 치료를 위한 인다졸릴벤즈아미드 유도체를 이용한 조합 요법 |
| EP3515436A1 (en) | 2016-09-23 | 2019-07-31 | Esanex, Inc. | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer |
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| EP4031132A4 (en) | 2019-09-19 | 2023-09-13 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | 核内受容体に対して活性の化合物 |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| CN117126097A (zh) * | 2020-06-11 | 2023-11-28 | 贝达药业股份有限公司 | 双环化合物及其应用 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN114213332B (zh) * | 2022-02-21 | 2022-05-17 | 深圳市人民医院 | 一种四氢吲唑类化合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4024862A1 (de) | 1990-08-04 | 1992-02-13 | Hoechst Ag | 4,5,6,7-tetrahydro-3-aryl-indazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| GB9812038D0 (en) * | 1998-06-04 | 1998-07-29 | Merck Sharp & Dohme | Therapeutic compound |
| GB9900222D0 (en) * | 1999-01-06 | 1999-02-24 | Merck Sharp & Dohme | Therapeutic compounds |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| WO2002020480A1 (en) * | 2000-09-06 | 2002-03-14 | Neurogen Corporation | Substituted fused pyrroleimines and pyrazoleimines |
| EP1431267A4 (en) | 2001-08-09 | 2004-12-22 | Ono Pharmaceutical Co | COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT |
| DE10148618B4 (de) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AU2003217870A1 (en) * | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pini-modulating compounds and methods of use thereof |
| AU2003288994A1 (en) | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| KR101617774B1 (ko) * | 2005-02-25 | 2016-05-04 | 에사넥스, 인코포레이티드 | 테트라히드로인돌론 및 테트라히드로인다졸론 유도체 |
| JPWO2006109846A1 (ja) | 2005-04-06 | 2008-11-20 | 武田薬品工業株式会社 | トリアゾール誘導体およびその用途 |
| US20080269193A1 (en) * | 2007-04-16 | 2008-10-30 | Kenneth He Huang | Tetrahydroindole and Tetrahydroindazole Derivatives |
-
2006
- 2006-02-27 KR KR1020137020400A patent/KR101617774B1/ko not_active Expired - Fee Related
- 2006-02-27 DK DK06736330.9T patent/DK1856057T3/en active
- 2006-02-27 SI SI200631875T patent/SI1856057T1/sl unknown
- 2006-02-27 TW TW095106716A patent/TWI382015B/zh not_active IP Right Cessation
- 2006-02-27 WO PCT/US2006/006988 patent/WO2006091963A1/en not_active Ceased
- 2006-02-27 ES ES06736330.9T patent/ES2527770T3/es active Active
- 2006-02-27 UA UAA200710606A patent/UA92907C2/uk unknown
- 2006-02-27 AU AU2006216441A patent/AU2006216441B2/en not_active Ceased
- 2006-02-27 EP EP11173186.5A patent/EP2380879B1/en active Active
- 2006-02-27 PL PL06736330T patent/PL1856057T3/pl unknown
- 2006-02-27 KR KR1020157005119A patent/KR20150029766A/ko not_active Abandoned
- 2006-02-27 CN CN200680010486.0A patent/CN101180275B/zh not_active Expired - Fee Related
- 2006-02-27 AR ARP060100720A patent/AR054186A1/es not_active Application Discontinuation
- 2006-02-27 GE GEAP200610280A patent/GEP20104994B/en unknown
- 2006-02-27 JP JP2007557244A patent/JP4377942B2/ja not_active Expired - Fee Related
- 2006-02-27 MX MX2007010227A patent/MX2007010227A/es active IP Right Grant
- 2006-02-27 NZ NZ560685A patent/NZ560685A/en not_active IP Right Cessation
- 2006-02-27 EP EP06736330.9A patent/EP1856057B1/en active Active
- 2006-02-27 PT PT67363309T patent/PT1856057E/pt unknown
- 2006-02-27 BR BRPI0607739-0A patent/BRPI0607739A2/pt not_active Application Discontinuation
- 2006-02-27 EA EA200701808A patent/EA013521B1/ru not_active IP Right Cessation
- 2006-02-27 US US11/363,449 patent/US7358370B2/en active Active
- 2006-02-27 NZ NZ588960A patent/NZ588960A/en not_active IP Right Cessation
- 2006-02-27 CA CA2598993A patent/CA2598993C/en active Active
- 2006-02-27 KR KR1020077021820A patent/KR20070114763A/ko not_active Ceased
-
2007
- 2007-08-14 IL IL185280A patent/IL185280A/en not_active IP Right Cessation
- 2007-08-22 NO NO20074274A patent/NO20074274L/no not_active Application Discontinuation
- 2007-09-11 MA MA30216A patent/MA29713B1/fr unknown
- 2007-12-19 US US11/959,784 patent/US7906529B2/en not_active Expired - Fee Related
-
2010
- 2010-10-19 US US12/907,571 patent/US7928135B2/en active Active
-
2011
- 2011-04-07 US US13/081,637 patent/US8309548B2/en not_active Expired - Fee Related
- 2011-04-15 AU AU2011201700A patent/AU2011201700B2/en not_active Ceased
-
2012
- 2012-11-05 US US13/669,016 patent/US20130137686A1/en not_active Abandoned
-
2014
- 2014-08-04 US US14/451,033 patent/US9656956B2/en not_active Expired - Fee Related
-
2017
- 2017-05-22 US US15/601,428 patent/US20170260174A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/408,959 patent/US20200071308A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054186A1 (es) | Derivados de tetrahidroindazolona y tetrahidroindolona | |
| UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
| AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| AR059674A1 (es) | Derivados de indol y pirazol, procesos de obtencion y composiciones farmaceuticas. | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR069765A1 (es) | 4-(4-ciano) 2- tioaril) dihidropirimidonas y su uso | |
| AR074543A1 (es) | Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PE20200298A1 (es) | Procesos e intermedios para hacer un inhibidor de jak | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR061083A1 (es) | Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| AR082446A1 (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
| CY1116439T1 (el) | Τριαζολοπυριδινες | |
| EA201690798A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |